The Chemistry and Cancer Program (CCP) seeks to discover small molecule chemicals capable of either antagonizing or agonizing regulatory pathways relevant to human cancer. Research efforts in the CCP proceed from one of two directions, chemistry-to-biology or biology-to-chemistry. In the former case, the discovery process starts with a novel natural product that is cytotoxic to cancer cells. This molecule, and specific derivatives synthesized by organic chemists, is then subjected to biochemical, genetic or molecular biological studies aimed at resolving its precise mode of action. Alternatively, knowledge of a specific biological pathway relevant to human cancer prompts attempts to identify small chemical antagonists or agonists of the pathway. The latter path is prosecuted by high throughput drug screening, rafional peptidomimetics, or preparation of synthetic analojgs of biological metabolites. In this context, the current scientific program themes are: 1) Identifying the Molecular Targets of Novel Cytotoxic Agents. 2) Biochemical Dissection of Novel. Cancer Cell-Specific Pathways. 3) Smac mimetics and other means of perturbing apoptosis with synthetic chemicals. 4) Regulation and targeting of the hypoxia response pathway with small molecules. The long-term objective of the CCP is to discover

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA142543-04S1
Application #
8711050
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-08-01
Project End
2015-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$75,000
Indirect Cost
$27,830
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Stallings, Nancy R; O'Neal, Melissa A; Hu, Jie et al. (2018) Pin1 mediates A?42-induced dendritic spine loss. Sci Signal 11:
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Pruitt, Sandi L; Werner, Claudia L; Borton, Eric K et al. (2018) Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System. Cancer Epidemiol Biomarkers Prev 27:1398-1406
Shay, Laura A; Baldwin, Austin S; Betts, Andrea C et al. (2018) Parent-Provider Communication of HPV Vaccine Hesitancy. Pediatrics 141:
Murphy, Caitlin C; Sigel, Bianca M; Yang, Edward et al. (2018) Adherence to colorectal cancer screening measured as the proportion of time covered. Gastrointest Endosc 88:323-331.e2
Taylor 4th, Clinton A; An, Sung-Wan; Kankanamalage, Sachith Gallolu et al. (2018) OSR1 regulates a subset of inward rectifier potassium channels via a binding motif variant. Proc Natl Acad Sci U S A 115:3840-3845
Deng, Mi; Gui, Xun; Kim, Jaehyup et al. (2018) LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562:605-609
Lee, Simon Craddock; Higashi, Robin T; Sanders, Joanne M et al. (2018) Effects of program scale-up on time to resolution for patients with abnormal screening mammography results. Cancer Causes Control 29:995-1005
Singal, Amit G; Tiro, Jasmin A; Murphy, Caitlin C et al. (2018) Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. Hepatology :
Ludlow, Andrew T; Wong, Mandy Sze; Robin, Jerome D et al. (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112

Showing the most recent 10 out of 501 publications